{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-002401","form_type":"8-K","ticker":"CLRB","cik":"0001279704","company_name":"Cellectar Biosciences, Inc.","filed_at":"2024-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.667841+00:00","generated_at":"2026-06-07T01:19:50.900600+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Cellectar announces positive pivotal trial data for iopofosine I 131 in WM","bullets":["CLOVER-WaM study met primary endpoint with 61% major response rate (p<0.0001), exceeding 20% statistical hurdle.","Overall response rate of 75.6% and 100% disease control in heavily pretreated, BTKi-refractory WM patients.","Median duration of response not yet reached at median 8-month follow-up; 76% remain progression-free.","No treatment-related discontinuations or deaths; Grade 3+ cytopenias manageable with no bleeding or febrile neutropenia beyond 2%."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-002401","json":"https://secwatch.observer/filing/0001104659-24-002401.json","markdown":"https://secwatch.observer/filing/0001104659-24-002401.md","text":"https://secwatch.observer/filing/0001104659-24-002401.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1279704/000110465924002401/0001104659-24-002401-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1279704/000110465924002401/tm242431d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T01:19:50.900600+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}